The authors could also correlate SAMHD1 expression with clinical outcome in 125 HL patients: Here, positive SAMHD1 expression in HRS cells was linked to inferior freedom from progression (FFP; 51% vs 70%), disease-specific survival (DSS; 72% vs 92%), and 10-year OS (OS; 69% vs 86%) compared to HL patients with SAMHD1-low/negative HRS cells [80]. This evidence concerns the gene SAMHD1 and Hodgkins lymphoma.